Literature DB >> 21365469

[Vagus stimulation. Mechanisms and current clinical importance in heart failure].

J Kuschyk1, M Borggrefe.   

Abstract

Increased sympathetic activity and reduced vagal activity are associated with increased mortality both after myocardial infarction and in heart failure; furthermore, vagal withdrawal has been documented to precede acute decompensation. Experimental studies indicate that increased parasympathetic activity by means of vagal stimulation may reduce mortality in animal models of post-infarction sudden cardiac death and of chronic heart failure. Initial clinical results demonstrate that chronic vagus nerve stimulation in heart failure patients with severe systolic dysfunction appears to be safe and tolerable and may improve quality of life, submaximal exercise capacity, and LV function. Vagus nerve stimulation derives these potential clinical benefits from multiple mechanisms of action. These include reduced heart rate, restoration of heart rate variability and baroreflex sensitivity, suppression of pro-inflammatory cytokines, and antiarrhythmic effects.

Entities:  

Mesh:

Year:  2011        PMID: 21365469     DOI: 10.1007/s00399-011-0119-0

Source DB:  PubMed          Journal:  Herzschrittmacherther Elektrophysiol        ISSN: 0938-7412


  23 in total

Review 1.  The inflammatory reflex.

Authors:  Kevin J Tracey
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

Review 2.  Parasympathetic nervous system and heart failure: pathophysiology and potential implications for therapy.

Authors:  Brian Olshansky; Hani N Sabbah; Paul J Hauptman; Wilson S Colucci
Journal:  Circulation       Date:  2008-08-19       Impact factor: 29.690

3.  Vagal stimulation and prevention of sudden death in conscious dogs with a healed myocardial infarction.

Authors:  E Vanoli; G M De Ferrari; M Stramba-Badiale; S S Hull; R D Foreman; P J Schwartz
Journal:  Circ Res       Date:  1991-05       Impact factor: 17.367

Review 4.  Vagus nerve stimulation: from pre-clinical to clinical application: challenges and future directions.

Authors:  Gaetano M De Ferrari; Peter J Schwartz
Journal:  Heart Fail Rev       Date:  2011-03       Impact factor: 4.214

5.  [The patient with chronic heart failure].

Authors:  D Bänsch; G Grönefeld
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2010-06

Review 6.  Vagus nerve stimulation, side effects, and long-term safety.

Authors:  E Ben-Menachem
Journal:  J Clin Neurophysiol       Date:  2001-09       Impact factor: 2.177

7.  Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction.

Authors:  H N Sabbah; H Shimoyama; T Kono; R C Gupta; V G Sharov; G Scicli; T B Levine; S Goldstein
Journal:  Circulation       Date:  1994-06       Impact factor: 29.690

8.  Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats.

Authors:  Meihua Li; Can Zheng; Takayuki Sato; Toru Kawada; Masaru Sugimachi; Kenji Sunagawa
Journal:  Circulation       Date:  2003-12-08       Impact factor: 29.690

9.  Autonomic mechanisms and sudden death. New insights from analysis of baroreceptor reflexes in conscious dogs with and without a myocardial infarction.

Authors:  P J Schwartz; E Vanoli; M Stramba-Badiale; G M De Ferrari; G E Billman; R D Foreman
Journal:  Circulation       Date:  1988-10       Impact factor: 29.690

10.  Chronic vagus nerve stimulation improves autonomic control and attenuates systemic inflammation and heart failure progression in a canine high-rate pacing model.

Authors:  Youhua Zhang; Zoran B Popovic; Steve Bibevski; Itaf Fakhry; Domenic A Sica; David R Van Wagoner; Todor N Mazgalev
Journal:  Circ Heart Fail       Date:  2009-09-22       Impact factor: 8.790

View more
  1 in total

1.  Short‑term vagal nerve stimulation improves left ventricular function following chronic heart failure in rats.

Authors:  Yan Li; Yan-Hua Xuan; Shuang-Shuang Liu; Jing Dong; Jia-Ying Luo; Zhi-Jun Sun
Journal:  Mol Med Rep       Date:  2015-04-07       Impact factor: 2.952

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.